In EGFR NSCLC, combining VEGF inhibitors with ICIs has emerged as a promising approach due to the potential of VEGF inhibitors to modulate the immune microenvironment, with preclinical and clinical evidence suggesting that they may promote T cell infiltration and immune activation [7,22]. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.